Legend Biotech Raises $226M in Public Offering to Fuel Cell Therapy Expansion
Event summary
- Legend Biotech priced a public offering of 7.7M ADSs at $29.35 each, raising ~$226M before expenses.
- Underwriters have a 30-day option to purchase an additional 1.155M ADSs.
- Proceeds will support expansion of CARVYKTI®, its CAR-T cell therapy for multiple myeloma.
- Offering expected to close June 23, 2026, subject to customary conditions.
The big picture
Legend Biotech’s $226M raise underscores the capital-intensive nature of scaling cell therapies, particularly as CAR-T treatments face pricing and reimbursement challenges. The move positions the company to compete more aggressively with larger biopharma players in an industry where end-to-end manufacturing and commercialization capabilities are critical. With Johnson & Johnson as a collaborator, Legend Biotech is betting on CARVYKTI as a cornerstone for broader therapeutic innovation.
What we're watching
- Execution Risk
- How Legend Biotech deploys the $226M to accelerate CARVYKTI’s market penetration and pipeline development.
- Market Dynamics
- Whether the offering signals renewed investor confidence in standalone cell therapy companies amid competitive pressures.
- Strategic Expansion
- The pace at which Legend Biotech diversifies beyond multiple myeloma into other cell therapy modalities.
Related topics